ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Chronic Obstructive Pulmonary Diseases Drugs Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-23D5552
Home | Market Reports | Health| Health Conditions| Respiratory Conditions
Global Chronic Obstructive Pulmonary Diseases Drugs Market Insights Forecast to 2028
BUY CHAPTERS

Global Chronic Obstructive Pulmonary Diseases Drugs Market Research Report 2025

Code: QYRE-Auto-23D5552
Report
July 2025
Pages:75
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Circassia Pharmaceuticals
Astrazeneca plc
GlaxoSmithKline PLC
Mylan NV
Boehringer Ingelheim
Pfizer Inc
Almirall
Abbott Laboratories
Novartis
Teva Pharmaceutical Industries

Chronic Obstructive Pulmonary Diseases Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Chronic Obstructive Pulmonary Diseases Drugs Market

Chronic Obstructive Pulmonary Diseases Drugs Market

The global market for Chronic Obstructive Pulmonary Diseases Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Chronic obstructive pulmonary disease (COPD) is a chronic bronchitis and/or emphysema characterized by airflow obstruction, which can further develop into a common chronic disease of cor pulmona and respiratory failure.It is related to the abnormal inflammatory reaction of harmful gases and harmful particles. The morbidity rate and fatality rate are very high, and the global morbidity rate over 40 years old is as high as 9% ~ 10%.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Diseases Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Diseases Drugs.
The Chronic Obstructive Pulmonary Diseases Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Obstructive Pulmonary Diseases Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Obstructive Pulmonary Diseases Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Chronic Obstructive Pulmonary Diseases Drugs Market Report

Report Metric Details
Report Name Chronic Obstructive Pulmonary Diseases Drugs Market
CAGR 5%
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Circassia Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Mylan, Boehringer Ingelheim, Pfizer, Almirall, Abbott Laboratories, Novartis, Teva Pharmaceutical Industries
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Diseases Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Chronic Obstructive Pulmonary Diseases Drugs Market report?

Ans: The main players in the Chronic Obstructive Pulmonary Diseases Drugs Market are Circassia Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Mylan, Boehringer Ingelheim, Pfizer, Almirall, Abbott Laboratories, Novartis, Teva Pharmaceutical Industries

What are the Application segmentation covered in the Chronic Obstructive Pulmonary Diseases Drugs Market report?

Ans: The Applications covered in the Chronic Obstructive Pulmonary Diseases Drugs Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Chronic Obstructive Pulmonary Diseases Drugs Market report?

Ans: The Types covered in the Chronic Obstructive Pulmonary Diseases Drugs Market report are Oral Medicine, Injection Medicine

Recommended Reports

Respiratory Diseases

Chronic Disease Drugs

Lung & Airway Drugs

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral Medicine
1.2.3 Injection Medicine
1.3 Market by Application
1.3.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Perspective (2020-2031)
2.2 Global Chronic Obstructive Pulmonary Diseases Drugs Growth Trends by Region
2.2.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Region (2020-2025)
2.2.3 Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Region (2026-2031)
2.3 Chronic Obstructive Pulmonary Diseases Drugs Market Dynamics
2.3.1 Chronic Obstructive Pulmonary Diseases Drugs Industry Trends
2.3.2 Chronic Obstructive Pulmonary Diseases Drugs Market Drivers
2.3.3 Chronic Obstructive Pulmonary Diseases Drugs Market Challenges
2.3.4 Chronic Obstructive Pulmonary Diseases Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Obstructive Pulmonary Diseases Drugs Players by Revenue
3.1.1 Global Top Chronic Obstructive Pulmonary Diseases Drugs Players by Revenue (2020-2025)
3.1.2 Global Chronic Obstructive Pulmonary Diseases Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chronic Obstructive Pulmonary Diseases Drugs Revenue
3.4 Global Chronic Obstructive Pulmonary Diseases Drugs Market Concentration Ratio
3.4.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Diseases Drugs Revenue in 2024
3.5 Global Key Players of Chronic Obstructive Pulmonary Diseases Drugs Head office and Area Served
3.6 Global Key Players of Chronic Obstructive Pulmonary Diseases Drugs, Product and Application
3.7 Global Key Players of Chronic Obstructive Pulmonary Diseases Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Obstructive Pulmonary Diseases Drugs Breakdown Data by Type
4.1 Global Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Type (2020-2025)
4.2 Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Type (2026-2031)
5 Chronic Obstructive Pulmonary Diseases Drugs Breakdown Data by Application
5.1 Global Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Application (2020-2025)
5.2 Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Chronic Obstructive Pulmonary Diseases Drugs Market Size (2020-2031)
6.2 North America Chronic Obstructive Pulmonary Diseases Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2020-2025)
6.4 North America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size (2020-2031)
7.2 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2020-2025)
7.4 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size (2020-2031)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size (2020-2031)
9.2 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2020-2025)
9.4 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size (2020-2031)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Circassia Pharmaceuticals
11.1.1 Circassia Pharmaceuticals Company Details
11.1.2 Circassia Pharmaceuticals Business Overview
11.1.3 Circassia Pharmaceuticals Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.1.4 Circassia Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
11.1.5 Circassia Pharmaceuticals Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.2.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
11.2.5 AstraZeneca Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.3.4 GlaxoSmithKline Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
11.3.5 GlaxoSmithKline Recent Development
11.4 Mylan
11.4.1 Mylan Company Details
11.4.2 Mylan Business Overview
11.4.3 Mylan Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.4.4 Mylan Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
11.4.5 Mylan Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.5.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
11.5.5 Boehringer Ingelheim Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.6.4 Pfizer Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
11.6.5 Pfizer Recent Development
11.7 Almirall
11.7.1 Almirall Company Details
11.7.2 Almirall Business Overview
11.7.3 Almirall Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.7.4 Almirall Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
11.7.5 Almirall Recent Development
11.8 Abbott Laboratories
11.8.1 Abbott Laboratories Company Details
11.8.2 Abbott Laboratories Business Overview
11.8.3 Abbott Laboratories Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.8.4 Abbott Laboratories Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
11.8.5 Abbott Laboratories Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.9.4 Novartis Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
11.9.5 Novartis Recent Development
11.10 Teva Pharmaceutical Industries
11.10.1 Teva Pharmaceutical Industries Company Details
11.10.2 Teva Pharmaceutical Industries Business Overview
11.10.3 Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Diseases Drugs Introduction
11.10.4 Teva Pharmaceutical Industries Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
11.10.5 Teva Pharmaceutical Industries Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Circassia Pharmaceuticals
Astrazeneca plc
GlaxoSmithKline PLC
Mylan NV
Boehringer Ingelheim
Pfizer Inc
Almirall
Abbott Laboratories
Novartis
Teva Pharmaceutical Industries
List of Tables
 Table 1. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Oral Medicine
 Table 3. Key Players of Injection Medicine
 Table 4. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Region (2020-2025)
 Table 8. Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Region (2026-2031)
 Table 10. Chronic Obstructive Pulmonary Diseases Drugs Market Trends
 Table 11. Chronic Obstructive Pulmonary Diseases Drugs Market Drivers
 Table 12. Chronic Obstructive Pulmonary Diseases Drugs Market Challenges
 Table 13. Chronic Obstructive Pulmonary Diseases Drugs Market Restraints
 Table 14. Global Chronic Obstructive Pulmonary Diseases Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Players (2020-2025)
 Table 16. Global Top Chronic Obstructive Pulmonary Diseases Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Diseases Drugs as of 2024)
 Table 17. Ranking of Global Top Chronic Obstructive Pulmonary Diseases Drugs Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Chronic Obstructive Pulmonary Diseases Drugs Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Chronic Obstructive Pulmonary Diseases Drugs, Headquarters and Area Served
 Table 20. Global Key Players of Chronic Obstructive Pulmonary Diseases Drugs, Product and Application
 Table 21. Global Key Players of Chronic Obstructive Pulmonary Diseases Drugs, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Chronic Obstructive Pulmonary Diseases Drugs Revenue Market Share by Type (2020-2025)
 Table 25. Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Chronic Obstructive Pulmonary Diseases Drugs Revenue Market Share by Type (2026-2031)
 Table 27. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Chronic Obstructive Pulmonary Diseases Drugs Revenue Market Share by Application (2020-2025)
 Table 29. Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Chronic Obstructive Pulmonary Diseases Drugs Revenue Market Share by Application (2026-2031)
 Table 31. North America Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Circassia Pharmaceuticals Company Details
 Table 47. Circassia Pharmaceuticals Business Overview
 Table 48. Circassia Pharmaceuticals Chronic Obstructive Pulmonary Diseases Drugs Product
 Table 49. Circassia Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025) & (US$ Million)
 Table 50. Circassia Pharmaceuticals Recent Development
 Table 51. AstraZeneca Company Details
 Table 52. AstraZeneca Business Overview
 Table 53. AstraZeneca Chronic Obstructive Pulmonary Diseases Drugs Product
 Table 54. AstraZeneca Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025) & (US$ Million)
 Table 55. AstraZeneca Recent Development
 Table 56. GlaxoSmithKline Company Details
 Table 57. GlaxoSmithKline Business Overview
 Table 58. GlaxoSmithKline Chronic Obstructive Pulmonary Diseases Drugs Product
 Table 59. GlaxoSmithKline Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025) & (US$ Million)
 Table 60. GlaxoSmithKline Recent Development
 Table 61. Mylan Company Details
 Table 62. Mylan Business Overview
 Table 63. Mylan Chronic Obstructive Pulmonary Diseases Drugs Product
 Table 64. Mylan Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025) & (US$ Million)
 Table 65. Mylan Recent Development
 Table 66. Boehringer Ingelheim Company Details
 Table 67. Boehringer Ingelheim Business Overview
 Table 68. Boehringer Ingelheim Chronic Obstructive Pulmonary Diseases Drugs Product
 Table 69. Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025) & (US$ Million)
 Table 70. Boehringer Ingelheim Recent Development
 Table 71. Pfizer Company Details
 Table 72. Pfizer Business Overview
 Table 73. Pfizer Chronic Obstructive Pulmonary Diseases Drugs Product
 Table 74. Pfizer Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025) & (US$ Million)
 Table 75. Pfizer Recent Development
 Table 76. Almirall Company Details
 Table 77. Almirall Business Overview
 Table 78. Almirall Chronic Obstructive Pulmonary Diseases Drugs Product
 Table 79. Almirall Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025) & (US$ Million)
 Table 80. Almirall Recent Development
 Table 81. Abbott Laboratories Company Details
 Table 82. Abbott Laboratories Business Overview
 Table 83. Abbott Laboratories Chronic Obstructive Pulmonary Diseases Drugs Product
 Table 84. Abbott Laboratories Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025) & (US$ Million)
 Table 85. Abbott Laboratories Recent Development
 Table 86. Novartis Company Details
 Table 87. Novartis Business Overview
 Table 88. Novartis Chronic Obstructive Pulmonary Diseases Drugs Product
 Table 89. Novartis Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025) & (US$ Million)
 Table 90. Novartis Recent Development
 Table 91. Teva Pharmaceutical Industries Company Details
 Table 92. Teva Pharmaceutical Industries Business Overview
 Table 93. Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Diseases Drugs Product
 Table 94. Teva Pharmaceutical Industries Revenue in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025) & (US$ Million)
 Table 95. Teva Pharmaceutical Industries Recent Development
 Table 96. Research Programs/Design for This Report
 Table 97. Key Data Information from Secondary Sources
 Table 98. Key Data Information from Primary Sources
 Table 99. Authors List of This Report


List of Figures
 Figure 1. Chronic Obstructive Pulmonary Diseases Drugs Picture
 Figure 2. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Type: 2024 VS 2031
 Figure 4. Oral Medicine Features
 Figure 5. Injection Medicine Features
 Figure 6. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Application: 2024 VS 2031
 Figure 8. Hospital Case Studies
 Figure 9. Clinic Case Studies
 Figure 10. Others Case Studies
 Figure 11. Chronic Obstructive Pulmonary Diseases Drugs Report Years Considered
 Figure 12. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Chronic Obstructive Pulmonary Diseases Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Region: 2024 VS 2031
 Figure 15. Global Chronic Obstructive Pulmonary Diseases Drugs Market Share by Players in 2024
 Figure 16. Global Top Chronic Obstructive Pulmonary Diseases Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Diseases Drugs as of 2024)
 Figure 17. The Top 10 and 5 Players Market Share by Chronic Obstructive Pulmonary Diseases Drugs Revenue in 2024
 Figure 18. North America Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Chronic Obstructive Pulmonary Diseases Drugs Market Share by Country (2020-2031)
 Figure 20. United States Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Chronic Obstructive Pulmonary Diseases Drugs Market Share by Country (2020-2031)
 Figure 24. Germany Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Nordic Countries Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Share by Region (2020-2031)
 Figure 32. China Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Share by Country (2020-2031)
 Figure 40. Mexico Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Share by Country (2020-2031)
 Figure 44. Turkey Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Chronic Obstructive Pulmonary Diseases Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Circassia Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
 Figure 48. AstraZeneca Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
 Figure 49. GlaxoSmithKline Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
 Figure 50. Mylan Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
 Figure 51. Boehringer Ingelheim Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
 Figure 52. Pfizer Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
 Figure 53. Almirall Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
 Figure 54. Abbott Laboratories Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
 Figure 55. Novartis Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
 Figure 56. Teva Pharmaceutical Industries Revenue Growth Rate in Chronic Obstructive Pulmonary Diseases Drugs Business (2020-2025)
 Figure 57. Bottom-up and Top-down Approaches for This Report
 Figure 58. Data Triangulation
 Figure 59. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

COPD Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Chronic Obstructive Pulmonary Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Research Report 2025
Chronic Lung Diseases Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Emphysema Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Obstructive Pulmonary Disease Therapeutics Market Research Report 2024
COPD Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Obstructive Pulmonary Disease Clinical Therapeutics Market Research Report 2025
Global Anti Asthmatics and COPD Drugs Market Research Report 2024
Global COPD Drugs Market Research Report 2024
Global COPD Inhaler Market Research Report 2025
Lung Pulmonary Airway Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Asthma and COPD Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Obstructive Pulmonary Disease COPD Treatment Market Insights Forecast to 2030
Global Chronic Obstructive Pulmonary Disorder Market Research Report 2024
Global COPD Drug Delivery Devices Market Insights Forecast to 2030
Global Chronic Respiratory Diseases Treatment Market Insights Forecast to 2030
Genetic COPD Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Emphysema Drug Market Research Report 2025

RELATED REPORTS

Global Asthma Monitoring Software Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5Y16546
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Respiratory Disease Test Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2Q16721
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Breath-activated Dry Powder Inhaler Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28Z16251
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Respiratory System Chronic Disease Inhalation Preparation Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-24R16205
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions